Lund — 18 October 2023 — Camurus today announced that the Nomination Committee for the Annual General Meeting (AGM), 2024 consists of the following persons, who together represent about 47.9 percent of the total number of shares and votes in Camurus based on the last known shareholder information:
- Per Sandberg, appointed by Sandberg Development AB,
- Arne Lööw, appointed by Fjärde AP-fonden,
- Magnus Welander, appointed by Fredrik Tiberg, and
- Per Olof Wallström, Chairman of the Board of Camurus
The Nomination Committee’s proposals will be presented in the Notice to the AGM 2024 and on Camurus’ website, www.camurus.com.
Shareholders who wish to submit proposals to the Nomination Committee are welcome to contact the Nomination Committee at the company’s address, Ideon Science Park, SE-223 70, Lund, Sweden. Proposals shall be submitted in due time before the AGM, but not later than 6 February 2024, to ensure that the proposals can be adequately considered by the Nomination Committee.
The AGM 2024 in Camurus will be held at 5:00 pm CET on 8 May 2024 in Lund. Shareholders who want to have a matter addressed at the AGM 2024 must submit such a proposal to the same address as above (subject “Annual General Meeting 2024”) by 20 March 2024 at the latest.
Camurus is a Swedish, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.
For more information
Per Olof Wallström, Chairman of the Board
Tel. +46 709 42 95 20
The information was submitted for publication at 07:00 am CET on 18 October 2023.